https://www.selleckchem.com/pr....oducts/crt0066101-di
Interferon beta (IFNb) is a safe first-line drug commonly used for relapsing-remitting (RR)-MS. Nevertheless, a considerable proportion of patients do not respond to IFNb treatment. Therefore, until now, a number of studies have investigated various markers that could predict the patients who would respond to IFNb therapy. The objective of this study was to identify reliable biomarkers to predict the efficacy of IFNb treatment in MS. In a group of 116 patients with clinically isolated syndrome (CIS) and RR-MS, we expl
Like
Comment
Share
